Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025

Larimar Therapeutics, Inc.

2024-Q1 EPS reported -$0.27

Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.
Cash, equivalents and marketable securities $239M after $161.8M public offering; runway extended into 2026.
Positive Phase 2 dose exploration: nomlabofusp generally well-tolerated, dose-dependent frataxin increases in skin and buccal cells.
First patient dosed in open-label extension (OLE) study of 25 mg daily; interim data on track for Q4 2024.
BLA submission targeted second half 2025; FDA discussions underway for accelerated approval using frataxin as surrogate endpoint.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Larimar Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $14.7 million, EPS $0.27 per share.

Period: first quarter ended March 31, 2024
Net income: $14.7 million
EPS: $0.27 per share
Result: reported results

Exact text from the filing

The Company reported a net loss for the first quarter of 2024 of $14.7 million, or $0.27 per share, compared to a net loss of $6.5 million, or $0.15 per share, for the first quarter of 2023.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056248

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.